Reported about 9 hours ago
Eli Lilly experiences significant growth, fueled by its top-selling diabetes and obesity treatments, Mounjaro and Zepbound, which generated over $10 billion in sales in the third quarter of 2025. The soaring demand for these GLP-1 receptor agonist drugs has prompted a bidding war for Metsera Inc., with Novo Nordisk proposing a $9 billion acquisition following Pfizer's earlier $5 billion bid. Despite their popularity, these treatments can be pricey and have varying effectiveness among patients, leading to ongoing interest in developing more accessible oral versions.
Source: YAHOO